Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bictegravir - Gilead Sciences

Next Previous
Search
Drug Profile

Bictegravir - Gilead Sciences

Alternative Names: Bictegravir controlled release - Gilead Sciences; GS 9883

Latest Information Update: 08 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Oxazepines; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III HIV-1 infections
  • Discontinued HIV infections

Most Recent Events

  • 05 Mar 2024 Efficacy and adverse event data from the phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
  • 03 Mar 2024 Updated efficacy data from the phase II/II ARTISTRY-1 trial in HIV infection presented at the Conference on retroviruses and opportunistic infections (CROI-2024)
  • 03 Mar 2024 Pharmacodynamics data from preclinical studies in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top